Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease

A therapeutic vaccine for human Chagas disease is under development by the Sabin Vaccine Institute Product Development Partnership. The aim of the vaccine is to significantly reduce the parasite burden of Trypanosoma cruzi in humans, either as a standalone product or in combination with conventional...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Hum Vaccin Immunother
Autori principali: Seid, Christopher A., Jones, Kathryn M., Pollet, Jeroen, Keegan, Brian, Hudspeth, Elissa, Hammond, Molly, Wei, Junfei, McAtee, C. Patrick, Versteeg, Leroy, Gutierrez, Amanda, Liu, Zhuyun, Zhan, Bin, Respress, Jonathan L., Strych, Ulrich, Bottazzi, Maria Elena, Hotez, Peter J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2016
Soggetti:
Research Papers
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5360114/
https://ncbi.nlm.nih.gov/pubmed/27737611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2016.1242540
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi